AAV介导的α-synuclein基因过表达致多巴胺能神经元损伤-一种制作轻度帕金森病大鼠模型的新方法

目的：研究过表达α-synuclein基因是否导致大鼠黑质纹状体选择性损伤,为帕金森病（parkinson’s disease, PD）大鼠模型的制备提供一种新的方法。方法:用腺相关病毒(adeno-associated virus, AAV)做载体,将人野生型α突触核蛋白(α-synuclein, NACP)引入大鼠脑内,观察大鼠行为学的改变,通过免疫组织化学染色观察其对黑质多巴胺能神经元细胞的影响,高效液相色谱（HPLC）检测纹状体多巴胺（DA）的含量。结果:α-synuclein基因过表达后大鼠出现自发性活动减少、爬行活动减慢、暂时性躯干震颤、竖毛等类似PD初期的症状和体征;大鼠脑黑质TH阳性神经元细胞随时间的延长出现数目减少,并且纹状体DA含量也出现减少,并且出现α-synuclein的积聚。结论:上述结果表明α-synuclein基因的过表达引起黑质多巴胺能神经元细胞的死亡,对大鼠的运动行为有一定的影响,产生类似于PD早期的症状与体征,与化学毒素（如6-OHDA, MPTP）诱导的动物模型相比,此法制作的动物模型可模拟PD缓慢发展的进程,为研究PD的病程进展及发病机制提供一个理想的动物模型。     

多巴胺代谢异常在帕金森病相关病理变化中的作用

帕金森病(Parkinson's disease,PD)是常见的中枢神经系统退行性疾病之一,其主要病理学特征是中脑黑质部的多巴胺(dopamine,DA)能神经元选择性丢失.虽然已发现基因易感性、衰老、环境毒素等因素与PD发病有关,但导致DA能神经元退行性死亡的细胞分子机制仍不明确.DA代谢是DA能神经元中的重要生理过...     

雌激素对多巴胺能神经元功能调节作用的研究进展

帕金森病（Parkinson‘s disease,PD)是中枢神经系统多巴胺（Dopamine,DA) 能神经元退行性疾病,其发病率具有明显的性别差异。性腺类固醇激素,尤其是雌激素,可在垂体、下丘脑、中脑边缘系统和黑质－纹状体（nigrostriatal,NS)系统等水平影响DA能神经递质系统的功能。而且,雌激素的使用剂量和时间的不同,可影响DA能神经元的活性。本文就雌激素与DA的关系及PD发病具有性别差异方面的新近进展作简要概述。     

毕赤酵母表达的neurturin对恒河猴帕金森氏病模型中黑质多巴胺能神经元的保护作用

帕金森氏病(PD)是由于多巴胺能神经元变性、坏死,导致黑质-纹状体系统的多巴胺含量下降而引起的一种神经系统退行性疾病,目前还没有一种很好的方法能使之治愈.Neurturin（NTN）能特异地作用于中脑多巴胺能神经元,对该类神经元具营养和保护作用.经静脉注射1-甲基-4-苯基-1,2,3,6-四氢吡啶(MPTP)诱导恒河猴产生帕金森氏病模型,并在NTN治疗组,注射MPTP之前48 h脑室内注射重组毕赤酵母表达的人NTN 1 mg. 结果表明：模型组猴均逐渐出现了PD症状,而NTN治疗组猴,PD症状比较轻或不明显;荧光分光光度法测定MPTP模型组猴黑质、壳核和尾状核多巴胺（DA）、5-羟色胺（5-HT）和5-羟吲哚乙酸（5-HIAA）的含量结果与正常对照组相比均显著降低,NTN治疗组猴的黑质、壳核和尾状核中的DA、5-HT和5-HIAA与对照组相比无显著性差异,而与模型组相比,DA、5-HT和5-HIAA含量均明显增加;光镜检查MPTP模型组猴黑质神经元细胞明显脱失,而NTN治疗组猴黑质神经元细胞丢失不明显,与正常对照组猴无差别.上述结果表明,制备的重组人NTN在恒河猴体内能保护中脑黑质多巴胺能神经元不受MPTP的损伤,使其DA含量及多巴胺能神经元维持正常,在MPTP存在下没有发生PD症状.     

帕金森病会表现为母系遗传吗?

<正>答:帕金森病(Parkinson disease,PD)是一种较常见的神经退行性疾病,通常是由于黑质-纹状体多巴胺(Dopamine,DA)能神经元的进行性损害导致的运动功能障碍。目前已经发现多个与家族性PD相关的基因,其中表现为常染色体显性遗传(AD)的基因有:突触核蛋白基因(α-synuclein,SNCA)(PARK1PARK4)、UCHL1基因(PARK5)、LRRK2基因     

帕金森病小鼠模型行为学检测方法的比较研究

目的比较目前常用的5种帕金森病(PD)小鼠模型行为学检测方法在PD研究中的作用。方法用MPTP建立C57BL小鼠PD模型,通过行为学检测(自主活动计数、滚轴实验、游泳实验、爬杆实验、悬挂实验)、免疫组织化学和荧光分光光度法,对比5种行为学检测方法的平均数与变异系数,观察MPTP对PD小鼠模型的行为学、黑质多巴胺(DA)神经元和纹状体酪氨酸羟化酶免疫反应阳性(TH-ir)神经纤维以及纹状体DA水平的影响。结果给与MPTP后,小鼠行为学计数降低,爬杆实验未能得到检测结果,悬挂实验变异系数很高,结果有明显的偶然性,滚轴实验结果变异系数中等,平均数呈现一定的上升趋势,自主活动计数中移动与站立和游泳实验的平均数则呈现明显的下降趋势,变异系数很低,而黑质DA神经元数目减少约58%,纹状体TH-ir神经纤维密度减低,纹状体DA水平明显降低约88%,两组相比差异有显著性(P<0.01)。结论MPTP所致的C57BL小鼠的神经病理、生化改变与PD患者近似,自主活动计数和游泳实验优于其他行为学检测方法。     

帕金森病模型大鼠脑内多巴胺与铁含量的关系

实验采用原子吸收分光光度法,快速周期伏安法,高效液相电化学检测等方法,研究以6－羟基多巴（6－OHDA）制备的帕金森病（PD）模型大鼠黑质内铁含量的变化。铁对多巴胺（DA）能神经元的直接毒性作用以及铁离子螯合剂甲磺酸去铁胺的神经保护作用。结果发现：（1）PD大鼠损毁侧黑质内铁含量为非标准PD大鼠的3倍左右;（2）PD大鼠损毁侧纹状体内铁含量无明显改变;（3）单纯注射6－OHDA的大鼠其损毁侧纹状体（CPu)DA的释放量和含量均明显降低;（4）侧脑室预先注射甲磺酸去铁胺,再重复上述实验,损毁侧CPu DA释放量和含量均无明显改变;（5）单侧黑质内注射40ug FeCl3后,大鼠损毁侧CPu内DA释放量和含量显著降低。上述结果提示,6－OHDA可导致CPu DA释放量及含量减少,此过程有铁的参与。由于铁可导致DA神经元死亡,因此铁含量的增加可能是DA含量减少的原因之一,甲磺酸去铁胺具有保护DA神经元的作用。     

间充质干细胞移植治疗帕金森病的作用机制研究进展

帕金森病(Parkinson’s Disease,PD)的主要病理改变是黑质多巴胺能神经元进行性变性致纹状体多巴胺递质浓度显著降低,从而出现运动障碍。目前,药物和外科手术治疗可一定程度改善早期PD的部分临床症状,但并不能阻止或逆转多巴胺能神经元变性。近些年,间充质干细胞(Mesenchymal Stem Cells,MSCs)移植作为治疗PD的最前沿方法,其疗效备受瞩目。本文就MSCs移植促进PD神经功能恢复的可能作用机制作一综述。     

帕金森病氧化应激机制及抗氧化药物治疗进展

帕金森病(PD)是一种仅次于阿尔兹海默病的第二大神经系统变性疾病,随着社会人口老龄化,PD发病率逐年增高,在65岁以上的老年人,患病率高达1%。PD主要临床表现为静止性震颤、肌强直、运动迟缓、姿势步态异常。目前病因仍未明确,疾病发生与很多因素相关,其主要病理特征为黑质多巴胺能神经元变性缺失。研究发现线粒体功能障碍、钙超载、铁离子的堆积、免疫炎症等均与氧化应激有关,能造成氧化性损伤,促进多巴胺能神经元凋亡,氧化应激在促进PD疾病发展中起到重要作用,因而越来越备受关注,抗氧化治疗在某种程度上为PD的治疗指出新的方向。本文就氧化应激引起DA神经元变性缺失的机制及抗氧化药物的治疗进展进行综述。     

帕金森氏病的病因及表现和治疗

帕金森氏病（Parkinsondiseas。PD）又称震颤麻痹,是发生于中年以上的中枢神经系统变性疾病,以震颤、肌强直反运动减少为主要临床特征入8厂年由英国医生帕金森门OO。。Parkinson）苗先报道。脑炎、动脉硬化、颅脑损伤、一氧化碳、锰、汞及某些抗精神病药物等中毒也可产生与原发性帕金森氏病类似的症状,这种继发者称为帕金森氏综合症。本文重点谈谈帕金森氏病的病因、表现和治疗。亚病因和发病机制到目前为止,Plj的确切病因尚未完全明确。患者中脑黑质多巴胺（DA偷神经元变性坏死、酪氨酸羟化酶（＊N）减少成活性降低,使脑纹状体多…     

miRNA in Parkinson's disease: From pathogenesis to theranostic approaches

Parkinson's disease (PD) is an age associated neurological disorder which is specified by cardinal motor symptoms such as tremor, stiffness, bradykinesia, postural instability, and non-motor symptoms. Dopaminergic neurons degradation in substantia nigra region and aggregation of αSyn are the classic signs of molecular defects noticed in PD pathogenesis. The discovery of microRNAs (miRNA) predicted to have a pivotal part in various processes regarding regularizing the cellular functions. Studies on dysregulation of miRNA in PD pathogenesis has recently gained the concern where our review unravels the role of miRNA expression in PD and its necessity in clinical validation for therapeutic development in PD. Here, we discussed how miRNA associated with ageing process in PD through molecular mechanistic approach of miRNAs on sirtuins, tumor necrosis factor-alpha and interleukin-6, dopamine loss, oxidative stress and autophagic dysregulation. Further we have also conferred the expression of miRNAs affected by SNCA gene expression, neuronal differentiation and its therapeutic potential with PD. In conclusion, we suggest more rigorous studies should be conducted on understanding the mechanisms and functions of miRNA in PD which will eventually lead to discovery of novel and promising therapeutics for PD.     

Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism?

Parkinson's disease (PD) is a major age-related neurodegenerative disorder characterized by a massive and specific loss of dopaminergic neurons of the substantia nigra pars compacta. The cellular alterations are clinically translated into an invalidating movement disability associated to three canonical symptoms that are bradykinesia, resting tremor and rigidity. The exact causes of this neuronal loss are unknown, but a network of evidences indicates a major contribution of orchestrated cell death processes, also known as apoptosis. Apoptotic cell death is a normal process, the alteration of which triggers several pathologies including cancer and neurodegenerative disorders. Exhaustive work has been done to delineate the cellular mechanisms responsible for the exacerbated cell death of dopaminergic neurons observed in PD. Overall, the oncogene p53 has been identified as a key effector protein.This review will focus on the clues linking p53 to the etiology of PD and the evidences that this protein may be at the center of multiple signaling cascades not only altered by mutations of various proteins responsible for familial cases of PD but also on more general sporadic cases of this devastating disease.     

Pathogenic Mutation in VPS35 Impairs Its Protection against MPP+ Cytotoxicity

Parkinson''s disease primarily results from progressive degeneration of dopaminergic neurons in the substantia nigra. Both neuronal toxicants and genetic factors are suggested to be involved in the disease pathogenesis. The mitochondrial toxicant 1-methyl-4-phenylpyridinium (MPP⁺) shows a highly selective toxicity to dopaminergic neurons. Recent studies indicate that mutation in the vacuolar protein sorting 35 (vps35) gene segregates with Parkinson''s disease in some families, but how mutation in the vps35 gene causes dopaminergic cell death is not known. Here, we report that enhanced VPS35 expression protected dopaminergic cells against MPP⁺ toxicity and that this neuroprotection was compromised by pathogenic mutation in the gene. A loss of neuroprotective functions contributes to the pathogenesis of VPS35 mutation in Parkinson''s disease.     

Primary Culture of Mouse Dopaminergic Neurons

Dopaminergic neurons represent less than 1% of the total number of neurons in the brain. This low amount of neurons regulates important brain functions such as motor control, motivation, and working memory. Nigrostriatal dopaminergic neurons selectively degenerate in Parkinson''s disease (PD). This progressive neuronal loss is unequivocally associated with the motors symptoms of the pathology (bradykinesia, resting tremor, and muscular rigidity). The main agent responsible of dopaminergic neuron degeneration is still unknown. However, these neurons appear to be extremely vulnerable in diverse conditions. Primary cultures constitute one of the most relevant models to investigate properties and characteristics of dopaminergic neurons. These cultures can be submitted to various stress agents that mimic PD pathology and to neuroprotective compounds in order to stop or slow down neuronal degeneration. The numerous transgenic mouse models of PD that have been generated during the last decade further increased the interest of researchers for dopaminergic neuron cultures. Here, the video protocol focuses on the delicate dissection of embryonic mouse brains. Precise excision of ventral mesencephalon is crucial to obtain neuronal cultures sufficiently rich in dopaminergic cells to allow subsequent studies. This protocol can be realized with embryonic transgenic mice and is suitable for immunofluorescence staining, quantitative PCR, second messenger quantification, or neuronal death/survival assessment.     

Partial depletion and repopulation of microglia have different effects in the acute MPTP mouse model of Parkinson’s disease

ObjectivesParkinson''s disease (PD) is a common neurodegenerative disorder characterized by the progressive and selective degeneration of dopaminergic neurons. Microglial activation and neuroinflammation are associated with the pathogenesis of PD. However, the relationship between microglial activation and PD pathology remains to be explored.Materials and MethodsAn acute regimen of MPTP was administered to adult C57BL/6J mice with normal, much reduced or repopulated microglial population. Damages of the dopaminergic system were comprehensively assessed. Inflammation‐related factors were assessed by quantitative PCR and Multiplex immunoassay. Behavioural tests were carried out to evaluate the motor deficits in MPTP‐challenged mice.ResultsThe receptor for colony‐stimulating factor 1 inhibitor PLX3397 could effectively deplete microglia in the nigrostriatal pathway of mice via feeding a PLX3397‐formulated diet for 21 days. Microglial depletion downregulated both pro‐inflammatory and anti‐inflammatory molecule expression at baseline and after MPTP administration. At 1d post‐MPTP injection, dopaminergic neurons showed a significant reduction in PLX3397‐fed mice, but not in control diet (CD)‐fed mice. However, partial microglial depletion in mice exerted little effect on MPTP‐induced dopaminergic injuries compared with CD mice at later time points. Interestingly, microglial repopulation brought about apparent resistance to MPTP intoxication.ConclusionsMicroglia can inhibit PD development at a very early stage; partial microglial depletion has little effect in terms of the whole process of the disease; and microglial replenishment elicits neuroprotection in PD mice.     

(ADP-ribose) polymerase 1 and AMP-activated protein kinase mediate progressive dopaminergic neuronal degeneration in a mouse model of Parkinson's disease

Genetic and epidemiologic evidence suggests that cellular energy homeostasis is critically associated with Parkinson''s disease (PD) pathogenesis. Here we demonstrated that genetic deletion of Poly (ADP-ribose) polymerase 1 completely blocked 6-hydroxydopamine-induced dopaminergic neurodegeneration and related PD-like symptoms. Hyperactivation of PARP-1 depleted ATP pools in dopaminergic (DA) neurons, thereby activating AMP-activated protein kinase (AMPK). Further, blockade of AMPK activation by viral infection with dominant-negative AMPK strongly inhibited DA neuronal atrophy with moderate suppression of nuclear translocation of apoptosis-inhibiting factor (AIF), whereas overactivation of AMPK conversely strengthened the 6-OHDA-induced DA neuronal degeneration. Collectively, these results suggest that manipulation of PARP-1 and AMPK signaling is an effective therapeutic approach to prevent PD-related DA neurodegeneration.     

Intranasal LPS-Mediated Parkinson’s Model Challenges the Pathogenesis of Nasal Cavity and Environmental Toxins

Accumulating evidence implicates the relationship between neuroinflammation and pathogenesis in idiopathic Parkinson''s disease (iPD). The nose has recently been considered a gate way to the brain which facilitates entry of environmental neurotoxin into the brain. Our study aims to build a PD model by a natural exposure route. In this report, we establish a new endotoxin-based PD model in mice by unilateral intranasal (i.n.) instillation of the lipopolysaccharides (LPS) every other day for 5 months. These mice display a progressive hypokinesia, selective loss of dopaminergic neurons, and reduction in striatal dopamine (DA) content, as well as α-synuclein aggregation in the SN, without systemic inflammatory and immune responses. This new PD model provides a tool for studying the inflammation-mediated chronic pathogenesis and searching for therapeutic intervention in glia-neuron pathway that will slow or halt neurodegeneration in PD.     

维生素D及其受体在帕金森病中的作用

帕金森病(Parkinson's disease,PD)是一种常见的中枢神经系统退行性疾病,引起帕金森病的发病机制至今尚未明确。帕金森病患者及老年人普遍存在维生素D缺乏,这可能是帕金森病的重要发病机制之一。由于维生素D具有免疫调节,抗氧化,调节神经营养因子,降低神经毒性的功能,能同时针对几种导致神经退行性病变因素发挥作用,特别是老年人纠正维生素D缺乏可能会阻止神经元的损失和PD相关的认知功能下降。因此补充维生素D可能成为治疗PD的方法。近年来研究发现,维生素D受体基因多态性与帕金森病的发病有相关性。该文就维生素D及其受体在帕金森病中可能发生的保护作用及其机制作一综述。     

Oxidative and nitrosative stress in Parkinson's disease

Parkinson's disease (PD) is a common neurodegenerative disorder marked by movement impairment caused by a selective degeneration of dopaminergic neurons. The mechanism for dopaminergic neuronal degeneration in PD is not completely clear, but it is believed that oxidative and nitrosative stress plays an important role during the pathogenesis of PD. This notion is supported by various studies that several indices of oxidative and nitrosative stress are increased in PD patients. In recent years, different pathways that are known to be important for neuronal survival have been shown to be affected by oxidative and nitrosative stress. Apart from the well-known oxidative free radicals induced protein nitration, lipid peroxidation and DNA damage, increasing evidence also suggests that some neuroprotective pathways can be affected by nitric oxide through S-nitrosylation. In addition, the selective dopaminergic neurodegeneration suggests that generation of oxidative stress associated with the metabolism of dopamine is an important contributor. Thorough understanding of how oxidative stress can contribute to the pathogenesis of PD will help formulate potential therapy for the treatment of this neurodegenerative disorder in the future.